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CASE REPORT
Development of stress-induced cardiomyopathy after cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy
Saad Ahmed Naved1, Sadiq Shoukat Parpia2, Huma Shoukat Ali3

Abstract
Pseudomyxoma Peritonei, a massive mucinous peritoneal
collection due to a rare epithelial neoplasm, can be
eﬀectively treated with Cytoreductive Surgery and
Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC).
A 43-year-old female, previously treated for mucinous
ovarian carcinoma with CRS-HIPEC, and total abdominal
hysterectomy and bilateral salpingo-oophorectomy,
presented with new-onset abdominal distension and early
satiety. She was diagnosed with Pseudomyxoma Peritonei.
After 48 hours of treatment with CRS-HIPEC, she presented
haemodynamically unstable with acute chest pain.
Electrocardiogram showed broad complex tachycardia
with ST depression in leads V3-6. Severe systolic
dysfunction with Ejection Fraction (EF) of 20% along with
severe pulmonary hypertension, visualized on
Echocardiography. A diagnosis of Stress-induced
Cardiomyopathy was established using InterTAK Diagnostic
Score.
Patients with CRS-HIPEC have presented with Stressinduced Cardiomyopathy. However, no specific relation
between the two has been established. This case report
discusses Stress-induced Cardiomyopathy as a
complication of CRS-HIPEC.
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Introduction
Stress-induced Cardiomyopathy, also known as Takotsubo
Cardiomyopathy Syndrome (TTS) is defined as temporary
left ventricular dysfunction due to stress and/or surgery.1
Pseudomyxoma Peritonei (PMP), a rare clinical condition
which occurs in 1–2 people in a million,2 is characterized
by massive amounts of mucous in the peritoneum mostly
due to a tumour of the appendix.3 Despite the slow spread,
the long term survival rate is 50% and 10%-30% at 5 and
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10 years, respectively.4 The gold standard treatment of PMP
is Cytoreductive Surgery and Hyperthermic Intraperitoneal
Chemotherapy (CRS-HIPEC)3 as it not only improves the
quality of life but has been shown to have better survival
rates.3 A retrospective multicentre series of 2,298 patients,
showed a 10-year survival rate of 63% after CRS-HIPEC.5
However, this treatment can induce physiological and
potentially pathological changes causing stress-induced
Cardiomyopathy which may lead to postoperative
morbidity and mortality. We present the case of a 43-yearold
female,
who
developed
stress-induced
Cardiomyopathy after undergoing CRS-HIPEC for PMP. This
case report highlights that stress-induced Cardiomyopathy
is a complication of CRS-HIPEC.

Case Report
A 43 years old female presented at Shifa International
Hospital, Islamabad on 3th March 2019 with complaints of
abdominal swelling and early satiety. Upon taking her
medical and surgical history, she had experienced similar
symptoms in the past and was diagnosed with Mucinous
Ovarian Adenocarcinoma. She underwent elective tumour
debulking. She later developed metastasis which were
treated by total abdominal hysterectomy and bilateral
salpingo-oophorectomy in August 2018. The patient had
received four cycles of neoadjunctive and adjunctive
chemotherapy, each with Carboplatin and Paclitaxel.
However, she recently started developing notable
abdominal swelling and early satiety again.
On evaluation, she was an alert and well-oriented
individual , with a height of 162 cm and weight 51 kg. Her
abdominal CT scan showed findings that were typical of
PMP with the suggestion of rupture of appendiceal
mucocole as the primary cause. However, no pathology
was found in her chest. Due to her current disease, she was
oﬀered CRS-HIPEC.
Preoperatively, she had good functional class and her
preoperative blood test was within the normal limit except
for mild anaemia (Hb=10.2 g/dl). Her electrocardiogram
and echocardiography showed sinus tachycardia and an
ejection fraction of 55%.
She underwent CRS which included splenectomy,
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appendectomy, cholecystectomy, excision of pelvic mass
adherent to the bladder, excision and repair of the bladder
and peritonectomy. This was followed by HIPEC with
Mitomycin 20 mg, at 42oC for 90 minutes. The
intraoperative blood loss was 2000 ml. She was transfused
750 ml of packed red blood cells and six litres of crystalloids
and 200 ml of Albumin. She remained stable
intraoperatively except for occasional episodes of
tachycardia and a need for low-dose norepinephrine
infusion to support haemodynamic parameters.
After the surgery, the patient was extubated and shifted to
Intensive Care Unit. After forty-eight hours of surgery, she
complained of chest pain and developed tachycardia,
hypotension, tachypnoea and decrease in oxygen
saturation (SpO2: 86% on room air). Her 12-lead ECG
showed broad-complex tachycardia and depression of ST
segment in leads V3-6. Her echocardiography (Table 1)
showed severe systolic dysfunction with EF of 20%, along
with severe pulmonary hypertension. Her cardiac enzymes
and BNP levels (Table 2) were also raised.
She was started on norepinephrine at 0.04 µg/kg/min.
Aspirin and clopidogrel were administered. Enoxaparin 60
mg subcutaneous was given on the following day. Her
respiration was supported by Bilevel Positive Airway
Pressure. Cardiology consult recommended coronary
angiography but was refused by the patient. Her condition
improved overtime and she was discharged on the seventh
post-operative day. On 2-weeks follow-up visit, her
echocardiogram revealed an improvement in ejection
fraction to 45%. No other abnormalities were noted, and
she was scheduled for regular follow-ups.
Table-1: Echocardiography reports.
Preoperative Echo EF: 55%, Trace AR, TR, mild mitral valve prolapse with mild MR
ECHO on POD 2

EF = 20%, mid antero-septum is akinetic, severe pulmonary
hypertension, mild MR, moderate TR, mild PR, severe cardiomyopathy

ECHO on POD 4

Normal left ventricular size with severe systolic dysfunction.
Estimated EF = 25%. Mid anteroseptum is akinetic.

Echo on POD 14

EF =40%

Table-2: Cardiac enzymes and BNP levels.

Discussion
CRS-HIPEC involves removal of the PMP aﬀected areas,
peritoneum and other intra-abdominal organs, followed by
perfusion of heated chemotherapy agent at 42-43oC for
1-2 hours directly within the abdominal cavity. Broadly, the
procedure includes three stages: Exploration,
Cytoreduction/debulking and Chemoperfusion. CRS has
minimal residual tumour and cytotoxicity is achieved by
delivering chemotherapeutic agents directly into the
peritoneal cavity.6
The morbidity after CRS-HIPEC can be either related to
surgery or chemotherapy. Chemotherapy eﬀects wound
healing and increases the risks of infectious complications.
The surgery-related morbidity includes abscess, fistula,
anastomotic leak, postoperative ileus, wound infection,
bleeding, thrombosis, pulmonary embolism, pleural
eﬀusion, pneumothorax, and cardiac arrhythmias.7
However, there is no case report showing a relationship
between CRS-HIPEC and stress cardiomyopathy.
TTS on electrocardiogram may mimic acute coronary
syndrome. It may also present with raised myocardial
enzymes even with no obstructive coronary artery disease.
However, coronary angiography is often normal or typically
shows less than 50% luminal stenosis. Most patients
recover completely, and the severely reduced left
ventricular systolic function recovers over four to eight
weeks.8
Stress-induced Cardiomyopathy is predominant in females.
Patients mostly present with chest pain and dyspnoea.
However, other more serious signs such as cardiogenic
shock, hypotension, arrhythmias, and cardiopulmonary
arrest are relatively common.8 TTS is most significantly
associated with an identifiable stressor, ranging from an
emotional stressful event without a physical component to
a physical stressor. Typically, physical stressors involve
major surgery, orthopaedic trauma, exacerbation of
obstructive airways disease, malignancy, chemotherapy
and infections.9

In TTS, as compared to ACS, initially the troponin
values are usually similarly raised, however, the peak
Nine days
values are noticeably lower. There is only slight
after the event
elevation in creatinine kinase and a remarkable
increase in the plasma BNP which continues to rise till
approximately 24–48 hours after symptom onset.10

Immediately
after the event

Six hours
after the event

Cardiac troponin I
(reference range in females
upto 15.6 pg/mL)

555.9 pg/mL

7397.3 pg/mL

Creatine kinase MB (CK-MB)
(reference range in females
up to 3.4 ng/mL)

4.2 ng/mL

30.5 ng/mL

-

Brain natriuretic peptide (BNP)
(reference range <100 pg/mL)

252.1 pg/mL

-

190 pg/mL

In order to correctly diagnosis Stress-induced
Cardiomyopathy, the International Takotsubo Registry
provides clinicians with the InterTAK Diagnostic Score.
According to the scoring system, the predicted
probability of TTS increases with the increasing score
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points of a patient. There is a chance of less than 1%, if the
patient has 30 score points. Similarly, patients with 50
points are 18% and patients with more than 70 points are
90% more likely to have TTS.10
In the present case, the patient had emotional stress, and
physical stress, adding up to a score of 62 points indicating
more than fifty percent probability of TTS. Although the
mechanism of TTS for this patient was uncertain, its
occurrence seems to be associated with anaesthesia,
surgery, post-operative pain, chemotherapy and excessive
stress inflicted by the outcome of this postoperative
treatment. This patient had chest pain, dyspnoea, T-wave
inversion in leads V3-V5 on ECG, mildly elevated cardiac
enzymes and BNP levels, and akinetic mid antero-septum
on echocardiography. All of which leads to a diagnosis of
stress-induced Cardiomyopathy.

magnetic resonance imaging; CRP: C-reactive protein; CRS:
cytoreductive surgery; CT: computerized tomography; DVT:
deep vein thrombosis; ECG: electrocardiogram; Echo:
echocardiogram; ESR: erythrocyte sedimentation rate; Hb:
Haemoglobin; HIPEC: hyperthermic intraperitoneal
chemotherapy; LVOTO: Left ventricular outflow tract
obstruction; METs: metabolic equivalent; MR: mitral
regurgitation; PMP: Pseudomyxoma peritonei; POD:
postoperative day; PR: pulmonary regurgitation; RV: Right
Ventricle; RWMA: regional wall motion abnormalities; SpO2:
peripheral capillary oxygen saturation; TR: tricuspid
regurgitation; TTE: transthoracic echocardiogram; TTS:
Takotsubo cardiomyopathy syndrome
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